Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease.
Background The majority of patients with Crohn's disease (CD) will not achieve endoscopic remission on current therapy. Addition of tofacitinib to biologics may improve remission rates. Methods We retrospectively assessed safety and clinical and endoscopic effectiveness of off-label tofacitinib and...
| Published in: | Inflammatory Bowel Diseases Vol. 28; no. 2; pp. 309 - 314 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Oxford University Press / USA
Feb2022
|
| Online Access: | View this record in EBSCOhost |